Marshwinds Advisory Co. Raises Stake in Bristol-Myers Squibb Company (BMY)
Marshwinds Advisory Co. increased its position in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 3.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 45,412 shares of the biopharmaceutical company’s stock after acquiring an additional 1,325 shares during the quarter. Marshwinds Advisory Co.’s holdings in Bristol-Myers Squibb were worth $2,530,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently modified their holdings of BMY. Ameriprise Financial Inc. lifted its stake in shares of Bristol-Myers Squibb by 18.7% during the first quarter. Ameriprise Financial Inc. now owns 15,547,051 shares of the biopharmaceutical company’s stock valued at $845,504,000 after acquiring an additional 2,451,390 shares during the period. Swiss National Bank lifted its stake in shares of Bristol-Myers Squibb by 27.2% during the first quarter. Swiss National Bank now owns 5,921,670 shares of the biopharmaceutical company’s stock valued at $322,020,000 after acquiring an additional 1,267,900 shares during the period. State Street Corp lifted its stake in shares of Bristol-Myers Squibb by 1.8% during the first quarter. State Street Corp now owns 68,893,779 shares of the biopharmaceutical company’s stock valued at $3,746,446,000 after acquiring an additional 1,223,457 shares during the period. Karp Capital Management Corp acquired a new position in shares of Bristol-Myers Squibb during the first quarter valued at $38,890,000. Finally, Canada Pension Plan Investment Board lifted its stake in shares of Bristol-Myers Squibb by 23.8% during the first quarter. Canada Pension Plan Investment Board now owns 3,362,609 shares of the biopharmaceutical company’s stock valued at $182,859,000 after acquiring an additional 646,000 shares during the period. 68.88% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/09/24/marshwinds-advisory-co-raises-stake-in-bristol-myers-squibb-company-bmy.html.
In other news, SVP Joseph C. Caldarella sold 9,340 shares of the business’s stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total value of $560,400.00. Following the transaction, the senior vice president now directly owns 46,297 shares of the company’s stock, valued at approximately $2,777,820. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Theodore R. Samuels II acquired 6,000 shares of the company’s stock in a transaction dated Wednesday, August 2nd. The stock was acquired at an average cost of $55.94 per share, for a total transaction of $335,640.00. Following the completion of the purchase, the director now directly owns 18,000 shares in the company, valued at $1,006,920. The disclosure for this purchase can be found here. 0.23% of the stock is owned by insiders.
Shares of Bristol-Myers Squibb Company (BMY) traded up 0.05% during midday trading on Friday, hitting $63.36. The company’s stock had a trading volume of 3,667,703 shares. The company has a 50-day moving average price of $58.94 and a 200 day moving average price of $56.02. The company has a market cap of $103.91 billion, a P/E ratio of 23.14 and a beta of 1.18. Bristol-Myers Squibb Company has a 1-year low of $46.01 and a 1-year high of $63.55.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.01. The company had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $5.09 billion. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The firm’s revenue was up 5.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.69 EPS. On average, equities research analysts predict that Bristol-Myers Squibb Company will post $2.98 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 1st. Stockholders of record on Friday, October 6th will be paid a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 2.46%. The ex-dividend date of this dividend is Thursday, October 5th. Bristol-Myers Squibb’s dividend payout ratio is 56.73%.
BMY has been the topic of several research reports. Vetr raised Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $58.88 price target on the stock in a research note on Monday, June 5th. BMO Capital Markets reissued a “sell” rating and issued a $49.00 target price on shares of Bristol-Myers Squibb in a research note on Monday, September 4th. Jefferies Group LLC reissued a “buy” rating and issued a $64.00 target price on shares of Bristol-Myers Squibb in a research note on Monday, June 5th. BidaskClub raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research note on Tuesday, June 27th. Finally, Deutsche Bank AG set a $55.00 target price on Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Monday, July 17th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $62.20.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.